



(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/706,599
Filing Date	November 11, 2003
First Named Inventor	Jackowski
Art Unit	1641
Examiner Name	
Attorney Docket Number	2132.135

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

8/3/06

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/706,599		
		Filing Date	November 11, 2003		
		First Named Inventor	Jackowski		
		Art Unit	1641		
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	2132.135

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓		G. CAIMI et al., "Erythrocyte Aggregation and Erythrocyte membrane properties in Type 2 Diabetes mellitus and in Vascular Atherosclerotic Disease", Thromb Haemost 83: 516-517 2000	
		H. DEMIROGLU et al., "Enhanced Erythrocyte Aggregation in Type 2 Diabetes with Late Complications", Experimental Clinical Endocrinol Diabetes 107 (1): 35-39 1999.	
		E. EYLAR et al., "The Contribution of Sialic Acid to the Surface Charge of the Erythrocyte", The Journal of Biological Chemistry 237(6): 1992-2000 1962.	
		M. GACZYNSKA et al., "Abnormal Degradation of Red Cell Membrane Proteins in Diabetes", Cytobios 75: 7-11 1993.	
		B.D. HAMES et al., "Antibodies as Tools" Instant Notes: Biochemistry, 2nd edition, Springer-Verlag New York 2000, pages 112-114.	
		B.D. HAMES et al., "Integral Membrane Proteins" Instant Notes: Biochemistry, 2nd edition, Springer-Verlag New York 2000, pages 125, 126, and 130.	
		M. MARTINEZ et al., "Alterations in Erythrocyte Aggregability in Diabetics: The Influence of Plasmatic Fibrinogen and Phospholipids of the Red Blood Cell Membrane", Clinical Hemorheology and Microcirculation 18: 253-258 1998.	
		A. PIWOWAR et al., "Concentration of Leukocyte Elastase in Plasma and Polymorphonuclear Neutrophil Extracts in type 2 Diabetes". Clinical Chemistry Lab Medicine 38(12) 1257-1261 2000.	
		M. SASAMOELISLO et al., "Fine Characterization of a Series of New Monoclonal Antibodies Directed against Glycophorin A", Vox Sanguinis 72: 185-191 1997.	
✓		A. SANTOS-SILVA et al., "Erythrocyte Damage and Leukocyte Activation in Ischemic Stroke", Clinica Chimica Acta 320: 29-35 2002.	

Examiner Signature	<i>[Signature]</i>	Date Considered	8/3/06
--------------------	--------------------	-----------------	--------






*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/706,599		
		Filing Date	November 11, 2003		
		First Named Inventor	Jackowski		
		Art Unit	1641		
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	2132.135

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		T. A. SCOTT et al., "Erythrocyte membrane", Concise Encyclopedia: Biochemistry and Molecular Biology, Third edition, Revised and Expanded, Walter de Gruyter, Berlin-New York 1997, pages 201-202.	
		L. SOLANG et al., "Diabetes Mellitus and Congestive Heart Failure", European Heart Journal 20: 789-795, 1999.	
		B. VENERANDO et al., "Acidic and Neutral Sialidase in the Erythrocyte Membrane of Type 2 Diabetic Patients", Blood 99 (3): 1064-1070 2002.	
		M. WEGNER et al., "Role of Neutral Endopeptidase 24.11 in AV Fistular Rat Model of Heart Failure", Cardiovascular Research 31: 891-898, 1996.	
		O. ZIEGLER et al. "Increased Erythrocyte Aggregation in insulin-Dependent Diabetes Mellitus and Its Relationship to Plasma Factors: A Multivariate Analysis", Metabolism 43 (9): 1182-1186, 1994.	

Examiner Signature		Date Considered	8/3/06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.